Sabra Healthcare REIT financials
$19.78−0.20%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $230.1M | $221.8M | $245.0M | $177.4M | $178.8M | $183.5M | $210.1M | $168.3M | $167.0M | $166.7M | $189.4M | $152.8M |
| Gross profit | $230.1M | $221.8M | $245.0M | $177.4M | $178.8M | $183.5M | $210.1M | $168.3M | $167.0M | $166.7M | $189.4M | $152.8M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$37.8M | $67.9M | $97.0M | $44.3M | $57.7M | $67.6M | $95.0M | $54.8M | $42.7M | $55.0M | $73.0M | $49.7M |
| Net income | -$25.2M | $40.9M | $27.2M | $22.5M | $65.5M | $40.3M | $46.7M | $29.8M | $24.0M | $26.3M | $17.2M | -$15.1M |
| Net margin | −11.0% | 18.4% | 11.1% | 12.7% | 36.7% | 22.0% | 22.2% | 17.7% | 14.4% | 15.7% | 9.1% | −9.9% |
| Diluted EPS | $-0.10 | $0.16 | $0.11 | $0.09 | $0.27 | $0.17 | $0.19 | $0.13 | $0.10 | $0.11 | $0.07 | $-0.07 |
| EBITDA | $18.6M | $121.5M | $149.1M | $95.4M | $105.4M | $111.1M | $137.3M | $97.5M | $99.7M | $101.0M | $80.3M | $92.9M |
| Operating cash flow | $85.8M | $98.4M | $87.4M | $100.0M | $81.0M | $80.3M | $80.0M | $97.7M | $80.1M | $52.8M | $88.0M | $83.2M |
| Free cash flow | $72.5M | $86.5M | $70.1M | $89.3M | $75.2M | $72.5M | $64.4M | $83.8M | $67.7M | $39.9M | $67.0M | $57.4M |
| Diluted shares | 252.3M | 256.0M | 253.2M | 243.6M | 240.9M | 240.3M | 240.0M | 237.0M | 233.8M | 233.4M | 236.5M | 231.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $231.6M | $116.5M | $71.5M | $200.6M | $95.2M | $22.7M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $2.63B | $2.67B | $2.53B | $2.59B | $2.48B | $2.39B |
| Total assets | $5.51B | $5.59B | $5.49B | $5.56B | $5.33B | $5.23B |
| Total liabilities | $2.76B | $2.80B | $2.67B | $2.74B | $2.62B | $2.53B |
| Shareholders' equity | $2.75B | $2.79B | $2.82B | $2.83B | $2.71B | $2.70B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology